FIGURE 1:

I-SPY 2 TRIAL study schema. Patients were randomized onto the control arm (paclitaxel treatment) or onto one of the multiple experimental drug treatment arms. DCE MRI was conducted at four timepoints to monitor treatment response via changes in MRI functional tumor volume. For the ACRIN 6698 Trial, an advanced four b-value DWI sequence was added at each of the MRI timepoints T0–T3, and test/retest repeatability scans were done on a subset of patients at T0 or T1. (We note that the T0–T3 nomenclature is used in this article for consistency with I-SPY 2, and differs from that defined in the ACRIN 6698 protocol.)